Efficacy and Tolerability of Pioglitazone in Patients with Type 2 Diabetes MellitusComparison with Other Oral Antihyperglycaemic Agents

被引：0
|
作者：
Giuseppe Derosa
机构：
[1] University of Pavia,Department of Internal Medicine and Therapeutics
来源：
Drugs | 2010年 / 70卷
关键词：
Metformin; Rosiglitazone; Pioglitazone; Acarbose; Sitagliptin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Diabetes mellitus is a debilitating disease that is estimated to affect 366 million people by the year 2030. Type 2 diabetes mellitus (T2DM) is characterized by a progressive decline in pancreatic β-cell function and increased insulin resistance, and accounts for approximately 90% of people with diabetes. Oral antihyperglycaemic agents are extensively used in the treatment of T2DM. Thiazolidinediones are insulin sensitizers developed specifically for T2DM, which act via activation of peroxisome proliferator-activated receptors (PPARs). Pioglitazone is a thiazolidinedione that displays high affinity for PPARγ1 and PPARγ2, which are predominately expressed in adipose tissue.
引用
收藏
页码：1945 / 1961
页数：16
相关论文
共 50 条
  • [31] Efficacy of Some Combination Regimens of Oral Hypoglycaemic Agents in Type 2 Diabetes Mellitus Patients
    Kumolosasi, Endang
    Yan, Gan Boon
    Wee, Chua Eng
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2015, 14 (07) : 1279 - 1284
  • [32] Efficacy and safety of alogliptin added to pioglitazone therapy in patients with type 2 diabetes
    Pratley, Richard
    Reusch, Jane
    Fleck, Penny
    Wilson, Craig
    Mekki, Qais
    DIABETES, 2008, 57 : A143 - A143
  • [33] Efficacy and safety of tofogliflozin administered for 52 weeks as monotherapy or combined with other oral hypoglycaemic agents in Japanese patients with type 2 diabetes
    Tanizawa, Y.
    Araki, E.
    Tobe, K.
    Terauchi, Y.
    Utsunomiya, K.
    Iwamoto, Y.
    Watada, H.
    Kaku, K.
    DIABETOLOGIA, 2013, 56 : S82 - S83
  • [34] COMPARE THE EFFICACY AND SAFETY OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS WITH OTHER ORAL HYPOGLYCEMIC AGENTS IN TYPE 2 DIABETES MELLITUS PATIENTS
    Konuru, Venkateswarlu
    Reddy, T. Rama Mohan
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2018, 9 (11): : 4963 - 4967
  • [35] EDGE study in Russian Federation: efficacy and safety of vildagliptine in comparison with other oral antidiabetic agents in patients with type 2 diabetes mellitus
    Galstyan, G. R.
    DIABETES MELLITUS, 2013, 16 (02): : 82 - 87
  • [36] Efficacy and tolerability of oral semaglutide in Japanese patients with type 2 diabetes mellitus: Analysis report from diabetes specialist clinics
    Inokuchi, Tetsuaki
    Fukumoto, Yoshihide
    Lee, Gendai
    Yokomizo, Yoshifumi
    Tanaka, Kokichi
    Chosa, Michiko
    Doi, Masaru
    Tamaki, Noboru
    Goto, Seiichi
    Ichikawa, Kojiro
    Kobayashi, Kazuo
    JOURNAL OF DIABETES INVESTIGATION, 2024, 15 (09) : 1202 - 1210
  • [37] Characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large US claims database
    Cai, B.
    Katz, L.
    Alexander, C. M.
    Williams-Herman, D.
    Girman, C. J.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2010, 64 (12) : 1601 - 1608
  • [38] Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency
    Harrower, ADB
    CLINICAL PHARMACOKINETICS, 1996, 31 (02) : 111 - 119
  • [39] Time to treatment initiation with oral antihyperglycaemic therapy in US patients with newly diagnosed type 2 diabetes
    Zhang, Q.
    Rajagopalan, S.
    Marrett, E.
    Davies, M. J.
    Radican, L.
    Engel, S. S.
    DIABETES OBESITY & METABOLISM, 2012, 14 (02): : 149 - 154
  • [40] The Effects of Diabetes Symptoms and Tolerability Issues on Non-Adherence with Oral Antidiabetic Agents among Patients with Type 2 Diabetes Mellitus
    Williams, Setareh A.
    Bolge, Susan
    Waterman, Fanta
    Pollack, Michael F.
    DIABETES, 2009, 58 : A320 - A321
12345